Introduction
Coronary heart disease (CHD) is the leading cause of death in the USA. One of the risk factors for heart disease is hypercholesterolaemia. Other known risk factors are cigarette smoking, hypertension, obesity, diabetes mellitus and a sedentary lifestyle. Numerous studies have demonstrated that early diagnosis and treatment reduces the incidence of atherosclerotic heart disease. The presence of risk factors for CHD can be established early in life. The Bogalusa Heart Study revealed a correlation between total serum cholesterol level and the presence of aortic and coronary fatty streaks in the pediatric population.! The sequence of the development of atheroma that begins with isolated foam cells in infants, to more accumulations in early childhood and finally progress to fatty streaks, has been well documented.s-> Autopsy studies on soldiers killed in the Vietnam and Korean wars also showed that early coronary atherosclerosis or its precursors begin in childhood or adolescence.s-> Currently, controversy exists regarding the decision to screen children for hypercholesterolaemia.sf Much of the controversy © Edward Arnold 1994 surrounds the fact that longitudinal studies have not been reported on the effect that dietary modification and/or drug therapy has in preventing the development and progression of CAD in children. The American Academy of Pediatrics (AAP) recommends selective screening of only those children with a family history of cardiovascular disease." Many children will be missed if a positive family history is relied upon particularly if one is dealing with young parents who may not have any symptoms of heart disease.w-'! The National Cholesterol Education Program (NCEP) recommends a population and an individualized approach to lower blood cholesterol. 12 The population approach aims to lower the average cholesterol among all American children through population-wide changes in nutrition as a step to reduce the incidence of CHD. The individualized approach is essentially the same as that recommended by the AAP.
The morbidity and mortality rates for CHD are higher in the USA for adults compared to many other countries. Children and adolescents in the USA have higher blood cholesterol levels and higher intake of saturated fats than those from other countries.Pi'" Children with high cholesterol levels are more likely to have those levels persist as adults. I 5-I 8 Studies have shown mean values for total and High Density Lipoprotein (HDL) cholesterol were shown to be related to dietary intake.t? In the study by Halfon et al. , 19 boys of Israel, North African and Asian origins were found to have an increase in HDL cholesterol at age 11 compared to values obtained at age seven while in most female groups the level decreased. However, this higher HD L cholesterol in boys does not persist as was shown in an earlier study by Halfon et al. 20 in boys at 17 years of age. In countries with high CHD mortality rates, both adults and children have relatively high serum cholesterol Ievels.u Serum cholesterol varies by age, race and sex. Hypercholesterolaemia is a risk factor for CHD. Since it is known that the process of atherosclerosis begins early in life and does not simply appear when one is an adult, it seems prudent that a reduction of the risk factors in childhood may decrease the incidence and mortality of CHD. Myocardial infarction secondary to CAD has been reported in children as young as 10 years of age who have homozygous FH.22
This review will focus on the diagnosis, interpretation and management of dyslipoproteinaemia in children with a brief description of the most common hyperlipidaemias.
Lipid metabolism
The major lipids in plasma are cholesterol, triglycerides, phospholipids and free fatty acids. Cholesterol and triglycerides are transported in the circulation in macromolecular complexes termed lipoproteins. The protein components of the complexes are known as apolipoproteins or apoproteins. These apoproteins serve as cofactors for plasma enzymes involved in lipid metabolism. The lipoproteins are classified into four major classes ( Figure 1 and and LDL. IDL are small remnants of VLDL metabolism and are either taken up via a hepatic cell membrane receptor or undergo conversion to LDL. LDL contains most of the serum cholesterol. HDL are secreted from the liver and small intestine as nascent discs composed of primarily phospholipids, apoA-I and apoA-U. The apoproteins serve as a cofactor for lecithin cholesterol acyltransferase (LCAT). The action of LCAT is to esterify cholesterol removed from peripheral sites. Apo-CII and ApoE on HDL are transferred to chylomicrons and apoA-I is transferred from chylomicrons to HDL. Chylomicrons are the largest lipoprotein and are secreted by the intestine after the ingestion of food. This lipoprotein contains mostly TG in addition to apoA, B48, C and E. Chylomicrons are cleared from the blood 12-14 hours after a meal.
The enzymes in the pathway of lipoproteinlipid metabolism are lipoprotein lipase (LPL), hepatic lipase (HL) and LCAT. Deficiency of any of the above enzymes will result in dyslipoproteinaernia.P Lipoprotein lipase (LPL) is present primarily in adipose tissue and striated muscle. The enzyme is synthesized in tissue parenchyma cells, secreted and transported to the endothelial surface of cells. LPL is required for the hydrolysis of TG in chylomicrons and most VLDL particles. In addition, apoC-II an activator protein on the surface of lipoprotein, is required for the action of LPL. Deficiency of LPL results in accumulation of chylomicrons and/or TG in plasma. Three inherited disorders of LPL have been identified: familial LPL deficiency, familial apoC-U deficiency and familial inhibitor of LPL. Diagnosis of LPL deficiency is made by measuring the enzyme activity in plasma after administering heparin.
Hepatic lipase (HL) is synthesized in liver cells. Its function is less well defined than LPL. HL functions in the lipolysis of VLDL and IDL during the later stages of formation of LDL.
LCAT is also synthesized in the liver and is responsible for the synthesis of cholesterol esters along with its cofactor, apoA-I, in plasma lipoprotein. As a result, cholesterol is removed from the cell membrane and becomes CE in the core of HDL. Deficiency of LCAT occurs as an autosomal recessive disease.
Lipoprotein levels
A number of factors influence the plasma lipoprotein levels in children. Age, sex, race and adiposity are known to affect these levels. 24 • 25 The lipoprotein profile changes from infancy to the adolescent period after which the profile will be closer to the adult values. 26 • 27 In the first decade of life, females have higher LDL, TG and lower HDL levels. During adolescence and sexual maturation, there is an increase in the total cholesterol level and LDL in both sexes while the HDL level decreases in males but remains constant or slightly increased in females.P A patient is classified as hyperlipidaemic if the level is greater than or equal to the 95th percentile values for corrected age and sex. In the case of HDL cholesterol, children with very low levels falling on the 5th percentile, are considered high risk.
Diagnosis
The diagnosis of hyperlipidaemia, primary or secondary, requires a careful approach. In order to evaluate a patient, accurate interpretation is necessary to determine which pattern of dyslipoproteinaemia is present. However, before this stage is reached, a few factors need to be considered.
Choice oflaboratory
The variability of cholesterol measurement data from laboratories is well documented-" which can be minimized by quality control. A laboratory's analysis should be traceable to a National Reference System for Cholesterol which is an accuracy-based system for cholesterol standardization such as that used in the USA. 29 The minimum requirement for accuracy of measurements include calibration of instrument, daily quality control assessment by use of common serum pool of known cholesterol concentrations, and establishing control limits to evaluate each day's analyses.w-" With the increased use of testing in private offices of practitioners, effective and efficient quality assurance has to be incorporated in the normal routine. Desktop analysers are in use in private paediatric practices and have been shown to provide reliable data with training and education on the operation of the instrument. 32. 33 Another source of variability relates to whether the lipid determinations are performed on fresh samples or on specimens that are stored for analysis at a later date.
Sampling
The simplest screening procedure is to measure a random total cholesterol in the nonfasting state. If this level is at or above the 95th percentile, a 12hour fasting lipoprotein profile is recommended to include TG, total and HDL cholesterol. However, looking only at a random cholesterol may not detect individuals with other abnormalities, such as elevated triglycerides, or low HDL choles-teroI. 34 .3S LDL can be estimated by the following formula:
This formula is applicable to fasting samples when the TG level is below 400 mgldl (4.5 mmol/I); chylomicrons are not present and type III hyperlipoproteinaemia is absent.V The characteristic of the plasma should also be noted: turbid, milky or clear, since this may provide clues to the abnormality present. It is important to confirm values before a specific hyperlipidaemic diagnosis is rendered. The profile should be verified by two or three measurements not only because of laboratory differences but also because of within-person variability which may be due to random fluctuation or to length of fasting. There are a host of other factors which may influence the result obtalned.» The total cholesterol values should be within 30 mgldl (0.78 mmol/I) of each other before they are averaged for interpretation. Once hyperlipidaemia is established, secondary causes have to be excluded. As part of the initial laboratory evaluation, we recommend the following: urinalysis; thyroid function studies (Thyroid Stimulating Hormone); electrolytes; blood urea nitrogen and creatinine; and liver function tests. The above should aid in eliminating 
Interpretation
Guidelines for interpreting quantitative lipid are provided in Table 3 .
This classification is recommended by NCEP for use in children with a family history of hypercholesterolaemia or atherosclerosis. 12 If the total cholesterol the LDL cholesterol is in the acceptable range, the recommendation is education regarding eating a healthy diet and on the risk factors of CAD. This is especially important in the adolescent years when certain habits are developed such as cigarette smoking. Thereafter, a reassessment of the lipoprotein profile is recommended in five years. If the level is in the borderline range, the 'step one' diet of NCEP is recommended and the patient should be re-evaluated in one year. When the level is in the high range, secondary causes of hyperlipidaemia should be excluded and the genetic basis of the abnormality should be evaluated (Table 4) .
Dietary intervention is indicated as the initial therapy followed by lipid lowering agents if an adequate trial of nutrition intervention is unsuccessful. 
Familial hypercholesterolaemia
Familial hypercholesterolaemia (FH) is the most common disorder of lipid metabolism recognized in childhood. This is an autosomal dominant disorder of insufficient activity of Low Density Lipoprotein (LDL) cholesterol receptors. In the heterozygous form, affected children usually have total cholesterol above 250 mg/dl (6.5 mmol/I) and lack physical signs and symptoms. In contrast, individuals with the homozygous state, are severely affected at an early age. Skin findings occur early and may be widespread. Tendon xanthomas, xanthelasma and arcus cornea are virtually always present. Plasma cholesterol levels are usually in the range of 50D-lOoo mg/dl (12.9-25.9 mmol/l). The majority of the cholesterol is LDL with values above 600 mg/dl (15.5 mmol/l) and HDL cholesterol are typically low. The diagnosis is suggested by a strong family history of early myocardial infarction and premature deaths. In the heterozygous form, the first line of treatment is dietary modification and pharmacotherapy if the diet trial is unsuccessful. For children with the homozygous form, treatment consists of plasmapheresis to decrease the blood cholesterol concentration.w Diet and lipid lowering agents will not reduce the cholesterol concentration significantly in this condition. Beyond plasmapheresis, other modes of intensive therapies include portacaval shunting and living transplantation.t? Early treatment is advocated, untreated patients seldom living beyond early adulthood.
Familial combined hypercholesterolaemia
Familial combined hypercholesterolaemia (FCH) is a heterogeneous group of lipid disorders characterized by abnormal levels of LDL and/or VLDL cholesterol.w-'? Four types have been identified of which type IIa is the most common (Table 4) . Family members will have either elevated levels of triglycerides, cholesterol or elevations of both. Stigmata of lipid deposition in the form of xanthomas are usually absent. However, some of these children often are obsese and hyperinsulinism and glucose intolerance are frequently found in adults. Typically, manifestations may not be apparent until the second and third decade of life. Thus physical signs and symptoms are absent in childhood. Laboratory analysis will reveal LDL cholesterol and/or triglyceride levels in the upper centiles and HDL cholesterol level may be low. Again the diagnosis is suggested by family history along with evaluation of laboratory values of the patient and family members. Treatment is the same as that for patients with FH, namely a low fat diet as a first step followed by medication if indicated.
Familial hyperalphalipoproteinaemia
Familial hyeralphalipoproteinaemia (FHAL) is an inherited elevation of HDL cholesterol in children with moderate cholesterol.40 This is a rare autosomal dominant trait. HDL cholesterol levels are over 70 mgldl (1.8 mmol/l) with a total cholesterol of 230-80 mgldl (5.9-7.2 mmol/l). A decrease in the incidence of CAD and a prolonged lifespan are attributed to the lower than normal risk for the development of premature atherosclerosis.
Familial hypertriglyceridaemia
Familial hypertriglyceridaemia (FHT) is a disorder characterized by production of abnormal VLDL, decreased removal and increased production of triglyceride.s! All three mechanisms result in elevated levels of triglyceride. This disorder is usually not detected before the age of 20. The endogenous form, classically known as type IV hyperlipoprotenaemia, is associated with high plasma VLDL, cholesterol and TG with a normal LDL cholesterol level. It can be diagnosed only by family studies which reveal TG level in the range of 200-1000 mg/dl (2.3-11.3 mmol/l) and elevation of total cholesterol. In children, the total cholesterol is frequently normal. Most children are asymptomatic and usually are detected by routine screening for other reasons. Treatment aims at reducing fat and saturated fat intake and controlling simple carbohydrate intake. An accelerated rate of atherosclerosis has not been consistently reported'? and thus the importance of dietary intervention is controversial.
Endogenous and exogenous hyperlipidaemia
Endogenous and exogenous hyperlipidaemia, classically type V, presents with the same laboratory features as type IV but differs by also having elevation of chylomicrons. This is a very rare disorder and is usually not expressed in childhood. A few cases in pre-adolescent children have been described.O Hyperchylomicronaemia (exogenous hypertriglyceridaemia) is a condition in which chylomicrons persist in the bloodstream after fasting. LPL and ApoC-II deficiencies are characteristic of this disorder. 44 Both occur rarely in childhood. Manifestations in childhood occur in the form of recurrent abdominal pain or recurrent bouts of pancreatitis. In adults, additional signs of eruptive xanthomas, lipemia retinalis, hepatosplenomegaly and pancreatitis are seen. Plasma TG levels range from 1000 mg/dl (11.3 mmol/l) to over 5000 mg/dl (56.5 mmol/l); levels as high as 10 000 mg/dl (112.9 mmol/l) have been reported.s> Therapy is focused on providing a diet low in long-chain fatty acids while assuring adequate calories for growth. Levels below 2000 mg/dl (22.6 mmol/l) are not associated with pancreatitis. The lipid lowering drugs can be used as an adjunct to dietary therapy but do not have a lasting effect. Here as in FHTG, there is no associated risk for early development of artherosclerosis.
Hyperapobetalipoproteinaemia
Hyperapobetalipoproteinaemia (HyperapoB) is characterized by elevated of apoB with a normal or moderately elevated level of LDL cholesterol. Total cholesterol can be mildly, moderately or markedly elevated. HyperapoB can be expressed in childhood.w
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Familial dysbetalipoproteinaemia Familial dysbetalipoproteinaemia (FDL) is rare disorder, classically type 3, and is characterized by abnormal beta (B) VLDL. The B-VLDL are enriched in cholesterol and apoE. The apoE is defective and does not bind normally to lipoprotein receptors. This leads to the accumulation of chylomicron and B-VLDL in plasma. Clinical features are varied and include tuberoeruptive xanthomas of the trunk, elbows and knees. The presence of palmar xanthomas along the palmar creases of the hands is virtually diagnostic and has not been described in any other disorder. 47 The diagnosis can be made clinically along with elevations of cholesterol and TG plus the presence of B-VLDL by electropheresis. This disorder is very responsive to dietary intervention and lipid lowering agents. FDL is rarely symptomatic in children but a few cases have been reported in adolescents.se
Polygenic hypercholesterolaemia
Polygenic hypercholesterolaemia encompasses those children who did not fit in any of the above categories but have high total cholesterol and high LDL cholesterol. The pattern of inheritance is not clear; in some FCH is the cause while others, other genetic causes exist. Diet weight control and regular exercise should be emphasized.
Management
As in adults, management of elevated blood cholesterol in children begins with dietary treatment and may need to be followed by pharmacotherapy ( Figure 2) . A multidisciplinary team of health professionals including physicians, nurses and registered dietitians or nutrition professional and health educator comprise the optimum staff to aid management.
Dietary manipulation
Dietary manipulation is almost always the first and only mode of treatment recommended for children. The efficacy and safety of lipid lowering pharmaceutical agents are not fully established for use in this age group. Hence current use of these drugs are limited to the most severely affected patients. The pharmacological agents act to either increase cholesterol loss or decrease production of lipoprotein. If no reduction occurs as a result of dietary interventions, further assessment is warranted. It must be determined if the care provider in the home understands the dietary principles, if there are unusual financial considerations, and if there are different settings where most of the meals are consumed (school, home or work). In addition, preparation of the meal by a parent versus household help can influence the diet. Moreover, the entire family should ideally be involved, if there is no contraindication, as this enhances compliance.
The goal of dietary intervention is to decrease the level of saturated fatty acids (SFA) and total fat while maintaining adequate caloric intake to assure continual growth and development. Growth failure has been reported in association with dietary treatment for hypercholesterolaemia.e? This has been attributed to a reduction of fat intake to less than 30% of total caloric requirement. Close supervision is essential in the monitoring of children and adolescents who are on a low fat diet.
Fat is available in saturated (SFA) , polyunsaturated (PFA) and monounsaturated (MFA) forms. SFA increases production of LDL cholesterol and decreases its disposal. MFA improves the ratio of LDL to HDL cholesterol without increasing plasma TG levels. PFA decreases the synthesis of VLDL, TO and cholesterol. 5G-52 The NCEP guideline for a cholesterol lowering diet recommends that the fat content not to exceed 30% of the daily caloric intake, with saturated fats, mono-and polyunsaturated fats equally represented. Daily cholesterol intake should be limited to 200 mg per day (5.2 mmolll). 52 The lipoprotein profile should be repeated six weeks after onset of dietary treatment and again at the end of three months. With good compliance, a 15% decrease can be expected. [53] [54] [55] If no improvement in the lipid pat- tern is found, a further reduction in fat intake is recommended as in step 2 of the NCEP guidelines. 52 ,53 For a general practitioner, this dietary modification translates most easily into advising a patient to substitute low fat snacks for high fat snacks, lean meat for fatty meat, low fat dietary products, and to consume smaller portions of meat, fish and poultry, limit the amount of eggs, bake instead of fry foods and use unsaturated oils for cooking. This is particularly useful in patients with only mild elevations of their lipid profile. However, one may need to employ the use of a nutritionist since very detailed analysis of a patient's diet may be needed. Fish oil supplements are being promoted as cholesterol-lowering and anti-atherogenic agents. Intake of fish is associated with reduced morbidity and mortality from atherosclerosis as evident in the Eskimo population.w This is attributed to the fatty acid component found almost exclusively in seafood. These FA are the omega-3FA (n-3FA) eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA). The actions ascribed to these acids are the lowering of TO level and anti-intimal thickening, platelet anti-aggregatory, anti-inflammatory and hypotensive effects. 57 ,58 The dosage required to achieve the lipid level desired has not been established and side effects such as obesity, vitamin A and D toxicity, and vitamin E deficiency have been reported. At present, the recommendation for children is to increase the intake of seafood rather than taking supplements.
Lipid lowering drug therapy
The institution of drug therapy is considered after an adequate trial of diet therapy. This does not mean discontinuance of the diet therapy. NCEP recommends the initiation of drug therapy if LDL cholesterol remains greater than 160 mg/dl (4.1 mmol/l) and a family history of premature cardiovascular disease exists and/or two or more other risk factors are present in the child or adolescent.52 Drug therapy may be initiated at an earlier age in cases of extreme elevation of blood cholesterol. The minimal goal of drug therapy is to achieve an LDL cholesterol less than 130 mgldl (3.4 mmol/l). Once drug therapy is begun, follow up after six weeks and every three months is necessary to determine the effects of therapy and to repeat the lipoprotein profile. In
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addition, growth parameters should be followed. After the therapeutic goal is reached, evaluation is recommended every six months to a year.
Bile acid binding resins
The most frequently used pharmacological agents (Table 5 ) are the bile acid binding resins, namely colestipol and cholestyramine.w.ev These agents act to increase cholesterol loss by preventing reabsorption of bile salts from the intestine leading to a decrease in total and LDL cholesterol. The dose is based on the LDL cholesterol level. These resins are given in powdered form and must be mixed in water or juice. It is generally recommended for this agent to be given at breakfast and dinner thus avoiding the lunch period since most children are in school. The most common side effects associated with the resins are gastrointestinal in the form of constipation, nausea, bloating, epigastric fullness and flatulence, and as with any medication, appropriate monitoring is needed.
Interference with the absorption of neutral fats, fat soluble vitamins, and folic acid may occur. In addition transient elevations in transaminase and alkaline phosphatase have been observed. The absorption of a number of drugs can be altered by the concurrent use of the resins; thus inquiries regarding the use of other medications should be made at every visit. Cholestyramine is the drug of choice for heterozygous familial and polygenic hypercholesterolaemia. The indications, safety, side-effects and activity of colestipol are the same as cholestyramine, and these two drugs can be used interchangeably. Patients with TG levels greater than 250 mg/dl (2.8 mmol/l) should not be treated with bile acid resins.
Fibric acid derivatives
This class of drugs reduces the incorporation of long chain fatty acids into TO thus reducing VLDL cholesterol synthesis and its release from the liver. In addition, they potentiate the activity of LPL. Oemfibrozil acts to lower TO, total and LDL cholesterol and raises HDL cholesterol values. In the Helsinki Heart Study.s' gemfibrozil was shown to cause a 10% decrease in total cholesterol, an 11% decrease in LDL, a 35% decrease in TO and raised HDL cholesterol by 11%. Gemfibrozil is useful in lipoprotein disorders characterized by elevation of VLDL, 
Nicotinicacid (niacin)
This is a water soluble B-vitamin which acts by decreasing VLDL synthesis in liver thus resulting in lower production of VLDL, LDL, total cholesterol and TO. It is useful alone and as well as in combination with bile acid resin. If the combination of diet therapy with a bile acid resin does not achieve the desired lipid levels, the addition of niacin is recommended. Side-effects include glucose intolerance, hyperuricaemia and elevation of liver transaminases. Frequent moni-toring is needed for these adnormalities. The aforementioned effects resolve with a reduction in dosage and are reversible when the drug is discontinued. Clearly, niacin should be avoided or used with caution in children with diabetes mellitus, liver disease and peptic ulcer disease. Flushing occurs in almost all patients and can be minimized if taken after meals or by taking aspirin the evening before the first dose then twice daily. Niacin can be given with or after meals.
HMG-CoA reductase inhibitors
Lovastatin (Mevacor) drug is an HMO-CoA (3-Hydroxy-3-Methylglutaryl Coenzyme) reductase inhibitor and acts to inhibit the rate limiting enzyme in cholesterol synthesis in the liver leading to decrease in intrahepatic production of cholesterol and a compensatory increase in LDL receptor activity. Lovastatin and other drugs in this class lower TG, total and LDL cholesterol and raise HDL. It is effective in FH and FCH, although it is not approved for use in children less than 18 years of age. Side-effects include nausea, headache and myalgia. The myalgia may progress to myopathy and is heralded by marked elevation of serum creatine phosphokinase.
Butyphenol
Butyphenol (Probucol) decreases elevated serum cholesterol level by reducing LDL concentration and also reduces the synthesis of apoA-1 and apoA-II, but is not used as a first line lipid lowering agent. The usefulness of this drug is limited by the fact that it causes a concurrent decrease in HDL cholesterol. Probucol is generally well tolerated, the most common side-effects being diarrhoea, flatulence, abdominal discomfort and nausea. Rarely, electrocardiogram changes may occur along with arrhythmias. The drug has a very long half-life and continues to be secreted from adipose tissue for about six months after discontinuation. Safety and efficacy in children have not been established. This drug is effective in FH.
Summary
Elevated blood cholesterol is one of the major risk factors for CHD. Cholesterol screening in childhood is an attempt to intercede in the development of the atherosclerotic process rather than intervening when a recognizable disease is declared in adulthood. High LDL levels promote the evaluation of atherosclerosis where high HDL levels are known to have a protective role in atherogenesis.e-If CAD begins in childhood, prevention is essential, particularly in those who are at risk. 6 3 • 64 The most dramatic consequence of ill health is death. Symptomatic CHD does not occur in children except in those with a genetic predisposition as in the homozygous state of FH.
Intuitively it makes sense that a prudent lifestyle will have certain health benefits. It is preventive medicine to incorporate eating a healthy diet and regular physical activity as a routine at a young age. This approach can reduce risk and avoid labelling an individual as having a disease especially if the entire family is involved.
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The damage that is caused by a diet high in fat and cholesterol does not become evident until adulthood; herein is one of the difficulties that exists in convincing parents, the public and practitioners of the need for early screening and monitoring of susceptible individuals.
